Myovant Sciences Ltd.
We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health diseases and other endocrine-related disorders. Our lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone, or GnRH, receptor antagonist. We are advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and advanced prostate cancer.
|Address||Clarendon House 2 Church Street, Hamilton HM 11, Bermuda|
|Phone Number||+1 (441) 824-8101|
|View Prospectus:||Myovant Sciences Ltd.|
|Revenues||$0.0 mil (last 12 months)|
|Net Income||$-20.6 mil (last 12 months)|
|Price range||$15.00 - $15.00|
|Est. $ Volume||$217.5 mil|
|Manager / Joint Managers||Citigroup/ Cowen and Company/ Evercore ISI/ Barclays|
|CO-Managers||JMP Securities/ Baird|
|Expected To Trade:||10/27/2016|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|